Logo image
Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis
期刊文章   開放取用(OA)   同儕審查

Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis

Shyi-Jou Chen, Yen-Ling Wang, Hueng-Chuen Fan, Wen-Tsung Lo, Chih-Chien WangHuey-Kang Sytwu
Clinical and Developmental Immunology, 卷.2012, 970789
2012
PMID: 22203863

摘要

Immunology and Allergy Immunology
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system, and CD4 + T cells form the core immunopathogenic cascade leading to chronic inflammation. Traditionally, Th1 cells (interferon - producing CD4+ T cells) driven by interleukin 12 (IL12) were considered to be the encephalitogenic T cells in MS and experimental autoimmune encephalomyelitis (EAE), an animal model of MS. Currently, Th17 cells (Il17-producing CD4 + T cells) are considered to play a fundamental role in the immunopathogenesis of EAE. This paper highlights the growing evidence that Th17 cells play the core role in the complex adaptive immunity of EAE/MS and discusses the roles of the associated immune cells and cytokines. These constitute the modern immunological basis for the development of novel clinical and preclinical immunomodulatory therapies for MS discussed in this paper. Copyright © 2012 Shyi-Jou Chen et al.

檔案與連結 (1)

url
https://doi.org/10.1155/2012/970789檢視
已出版(紀錄版本) 開放

相關連結

指標

1 檢視次數

詳細資料

Logo image